Statins in the treatment of central nervous system autoimmune disease

Martin S. Weber, Sawsan Youssef, Shannon E. Dunn, Thomas Prod'homme, Oliver Neuhaus, Olaf Stuve, John Greenwood, Lawrence Steinman, Scott S. Zamvil

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, are widely prescribed for their cholesterol-lowering properties to reduce atherogenesis and cardiovascular morbidity. Over recent years, statins have also been shown to exert pleiotropic immunomodulatory effects that might be of therapeutic benefit in autoimmune disorders. The primary mechanism by which statins alter immune function appears to be mediated through the inhibition of post-translational protein prenylation of small GTP-binding proteins and is largely independent of lipid-lowering. In experimental autoimmune encephalomyelitis (EAE), the mouse model for multiple sclerosis (MS), statins prevent or reverse paralysis and were recently shown to exert synergistic benefit when combined with agents approved for MS therapy. Based primarily upon the beneficial effects in EAE, statins are now being tested in patients in MS clinical trials.

Original languageEnglish (US)
Pages (from-to)140-148
Number of pages9
JournalJournal of Neuroimmunology
Volume178
Issue number1-2
DOIs
StatePublished - Sep 2006

Fingerprint

Autoimmune Diseases of the Nervous System
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Central Nervous System Diseases
Multiple Sclerosis
Autoimmune Experimental Encephalomyelitis
Protein Prenylation
Therapeutics
GTP-Binding Proteins
Paralysis
Atherosclerosis
Oxidoreductases
Cholesterol
Clinical Trials
Morbidity
Lipids

Keywords

  • Autoimmune disease
  • Combination therapy
  • EAE
  • MS
  • Statins

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Weber, M. S., Youssef, S., Dunn, S. E., Prod'homme, T., Neuhaus, O., Stuve, O., ... Zamvil, S. S. (2006). Statins in the treatment of central nervous system autoimmune disease. Journal of Neuroimmunology, 178(1-2), 140-148. https://doi.org/10.1016/j.jneuroim.2006.06.006

Statins in the treatment of central nervous system autoimmune disease. / Weber, Martin S.; Youssef, Sawsan; Dunn, Shannon E.; Prod'homme, Thomas; Neuhaus, Oliver; Stuve, Olaf; Greenwood, John; Steinman, Lawrence; Zamvil, Scott S.

In: Journal of Neuroimmunology, Vol. 178, No. 1-2, 09.2006, p. 140-148.

Research output: Contribution to journalArticle

Weber, MS, Youssef, S, Dunn, SE, Prod'homme, T, Neuhaus, O, Stuve, O, Greenwood, J, Steinman, L & Zamvil, SS 2006, 'Statins in the treatment of central nervous system autoimmune disease', Journal of Neuroimmunology, vol. 178, no. 1-2, pp. 140-148. https://doi.org/10.1016/j.jneuroim.2006.06.006
Weber, Martin S. ; Youssef, Sawsan ; Dunn, Shannon E. ; Prod'homme, Thomas ; Neuhaus, Oliver ; Stuve, Olaf ; Greenwood, John ; Steinman, Lawrence ; Zamvil, Scott S. / Statins in the treatment of central nervous system autoimmune disease. In: Journal of Neuroimmunology. 2006 ; Vol. 178, No. 1-2. pp. 140-148.
@article{b12c72bc5b714065af151bfa9145ddc4,
title = "Statins in the treatment of central nervous system autoimmune disease",
abstract = "Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, are widely prescribed for their cholesterol-lowering properties to reduce atherogenesis and cardiovascular morbidity. Over recent years, statins have also been shown to exert pleiotropic immunomodulatory effects that might be of therapeutic benefit in autoimmune disorders. The primary mechanism by which statins alter immune function appears to be mediated through the inhibition of post-translational protein prenylation of small GTP-binding proteins and is largely independent of lipid-lowering. In experimental autoimmune encephalomyelitis (EAE), the mouse model for multiple sclerosis (MS), statins prevent or reverse paralysis and were recently shown to exert synergistic benefit when combined with agents approved for MS therapy. Based primarily upon the beneficial effects in EAE, statins are now being tested in patients in MS clinical trials.",
keywords = "Autoimmune disease, Combination therapy, EAE, MS, Statins",
author = "Weber, {Martin S.} and Sawsan Youssef and Dunn, {Shannon E.} and Thomas Prod'homme and Oliver Neuhaus and Olaf Stuve and John Greenwood and Lawrence Steinman and Zamvil, {Scott S.}",
year = "2006",
month = "9",
doi = "10.1016/j.jneuroim.2006.06.006",
language = "English (US)",
volume = "178",
pages = "140--148",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Statins in the treatment of central nervous system autoimmune disease

AU - Weber, Martin S.

AU - Youssef, Sawsan

AU - Dunn, Shannon E.

AU - Prod'homme, Thomas

AU - Neuhaus, Oliver

AU - Stuve, Olaf

AU - Greenwood, John

AU - Steinman, Lawrence

AU - Zamvil, Scott S.

PY - 2006/9

Y1 - 2006/9

N2 - Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, are widely prescribed for their cholesterol-lowering properties to reduce atherogenesis and cardiovascular morbidity. Over recent years, statins have also been shown to exert pleiotropic immunomodulatory effects that might be of therapeutic benefit in autoimmune disorders. The primary mechanism by which statins alter immune function appears to be mediated through the inhibition of post-translational protein prenylation of small GTP-binding proteins and is largely independent of lipid-lowering. In experimental autoimmune encephalomyelitis (EAE), the mouse model for multiple sclerosis (MS), statins prevent or reverse paralysis and were recently shown to exert synergistic benefit when combined with agents approved for MS therapy. Based primarily upon the beneficial effects in EAE, statins are now being tested in patients in MS clinical trials.

AB - Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, are widely prescribed for their cholesterol-lowering properties to reduce atherogenesis and cardiovascular morbidity. Over recent years, statins have also been shown to exert pleiotropic immunomodulatory effects that might be of therapeutic benefit in autoimmune disorders. The primary mechanism by which statins alter immune function appears to be mediated through the inhibition of post-translational protein prenylation of small GTP-binding proteins and is largely independent of lipid-lowering. In experimental autoimmune encephalomyelitis (EAE), the mouse model for multiple sclerosis (MS), statins prevent or reverse paralysis and were recently shown to exert synergistic benefit when combined with agents approved for MS therapy. Based primarily upon the beneficial effects in EAE, statins are now being tested in patients in MS clinical trials.

KW - Autoimmune disease

KW - Combination therapy

KW - EAE

KW - MS

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=33748175510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748175510&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2006.06.006

DO - 10.1016/j.jneuroim.2006.06.006

M3 - Article

C2 - 16860400

AN - SCOPUS:33748175510

VL - 178

SP - 140

EP - 148

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -